Novartis’ Zelnorm Has 25% Adoption Rate Among Specialists After 2 Months
Executive Summary
The uptake of Novartis' irritable bowel syndrome therapy Zelnorm will accelerate after physicians obtain more "feedback" from early users, U.S. Commercial Operations General Manager Kurt Graves said Oct. 17 during a Novartis R&D briefing in New York City
You may also be interested in...
Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
Novartis plans to launch a national DTC campaign for its irritable bowel syndrome agent Zelnorm early in the third quarter, the company announced during its July 21 investor conference call
Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
Novartis plans to launch a national DTC campaign for its irritable bowel syndrome agent Zelnorm early in the third quarter, the company announced during its July 21 investor conference call
FDA Objects To Novartis IBS Ads; Claims Are Zelnorm-Specific, Agency Says
Novartis' irritable bowel syndrome awareness ads are too specific to Zelnorm to be considered "reminder" ads, FDA says in an untitled letter to the company